{"prompt": "['5.3', 'Randomization or Treatment Allocation', 'This is an open-label, single-arm study. All subjects who provide signed informed consent to', 'participate in this study and satisfy all eligibility requirements will receive lenvatinib in', 'combination with pembrolizumab. There is no randomization in this study.', '5.4 Stratification', 'There will be no stratification as this is a single-arm trial.', '5.5 Concomitant Medications/Vaccinations', 'Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed', 'during the ongoing trial. If there is a clinical indication for one of these or other medications', 'or vaccinations specifically prohibited during the trial, discontinuation from trial therapy or', 'vaccination may be required. The final decision on any supportive therapy or vaccination', 'rests with the investigator.', '5.5.1 Acceptable Concomitant Medications', \"All treatments that the investigator considers necessary for a participant's welfare may be\", 'administered at the discretion of the investigator in keeping with the community standards of', 'medical care. All concomitant medication will be recorded on the case report form (CRF)', 'including all prescription, over-the-counter (OTC), herbal supplements, and IV medications', 'and fluids. If changes occur during the trial period, documentation of drug dosage,', 'frequency, route, and date may also be included on the CRF.', 'All concomitant medications received within 28 days before the first dose of trial treatment', 'and 30 days after the last dose of trial treatment should be recorded. Concomitant', 'medications administered after 30 days after the last dose of trial treatment should be', 'recorded for SAEs and ECIs as defined in Section 7.2. Any medication that is considered', \"necessary for the subject's health and that is not expected to interfere with the evaluation of\", 'or interact with lenvatinib or pembrolizumab may be continued during the study.', 'For clarification, the following concomitant medications are also allowed:', 'Antiemetics and antidiarrheal medications are allowed according to standard clinical', 'practice if indicated', 'Granulocyte colony-stimulating factors (G-CSF or GM-CSF) are allowed if used per', 'clinical guidelines (e.g. ASCO guidelines)', 'Erythropoietin (e.g. epoetin alfa and darbepoetin alfa ) is allowed if used per clinical', 'guidelines (e.g. ASCO guidelines) but the subject should be carefully monitored for', 'increases in red blood cell (RBC) counts', '31']['Transfusions if clinically indicated', 'Thyroid hormone suppressive therapy (including therapy to treat hypothyroidism and', 'hyperthyroidism)', 'Adjuvant hormonal therapy for history of definitively treated breast cancer or', 'localized prostate cancer', 'Low-molecular-weight heparin', 'Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and anticoagulants', 'including low-molecular-weight heparin, warfarin, anti-Xa agents or direct thrombin', 'inhibitors are permissible but should be used with caution', 'Bisphosphonates or denosumab', 'Medications for treatment of infusion reaction associated with pembrolizumab (see', 'Section 5.2.3.2)', 'Antihypertensive therapy (including additional antihypertensive treatment as', 'appropriate if BP increases once the patient has been enrolled)', '5.5.1.1 Drug-Drug Interactions', \"Lenvatinib's weak in vitro inhibitory and induction potential on cytochrome P450 (CYP\", 'P450) enzymes (Study No. XT063020) suggests a low risk of lenvatinib interference with the', 'PK of other drugs metabolized by CYP P450 enzymes which are co-administered in usual', 'clinic practice. Nonclinical studies identify CYP3A4 as an important enzyme responsible for', 'human hepatic metabolism of lenvatinib. However, clinical studies conducted to test these', 'findings showed that co-administration of lenvatinib with CYP3A4/P-glycoprotein (P-gp)', 'inhibitors or inducers is not of clinical concern.', 'No formal pharmacokinetic drug interaction studies have been conducted with', 'pembrolizumab. Pembrolizumab is a monoclonal antibody; pharmacokinetic interactions', 'with lenvatinib (and vice-versa) are not expected.', '5.5.2 Prohibited Concomitant Medications', 'Participants are prohibited from receiving the following therapies during the Pre-Treatment', 'and Treatment Phases of this trial:', 'Antineoplastic systemic chemotherapy or biological therapy', 'Immunotherapy not specified in this protocol', 'Chemotherapy not specified in this protocol', 'Investigational agents other than pembrolizumab', '32']\n\n###\n\n", "completion": "END"}